MedTrace Logo

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

NCT07522151 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 874

Last updated 2026-05-13

No results posted yet for this study

Summary

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

Conditions

  • Locally Advanced Gastric or Gastroesophageal Junction Cancer

Interventions

DRUG

Adebrelimab plus S-1 and oxaliplatin

Adebrelimab plus S-1 and oxaliplatin

DRUG

Adebrelimab blank preparation plus S-1 and oxaliplatin.

Adebrelimab blank preparation plus S-1 and oxaliplatin.

Sponsors & Collaborators

  • Shanghai Shengdi Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-07
Primary Completion
2029-12-31
Completion
2034-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07522151 on ClinicalTrials.gov